Immix Biopharma suspends at-the-market equity offering under Sales Agreement with ThinkEquity

Immix Biopharma, Inc.

Suspended prospectus supplement dated July 14, 2023; no sales of common stock until new filing.
Sales Agreement with ThinkEquity LLC remains in full force and effect.
No reason given for suspension; company may resume after filing new supplement.
Suspension removes immediate dilution risk but pauses potential capital raising.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.